UK Department for International Trade

A number of companies shown here with profiles and logos are financially supported by the UK government's Tradeshow Access Programme.

Chris Howie
Sector specialist 

Alderley Park Ltd

The UK's largest bioscience campus: dedicated to helping shape the future of the world's health. Alderley Park offers exceptional bioscience facilities for R&D focused life science companies at every stage of their life-cycle, from start-up to global corporate. Its Mereside campus is part of Manchester Science Partnerships, one of the leading science and technology park operators in Europe. Offering 1m sq ft state-of-the-art chemistry, biology and pathology labs, dedicated incubator facilities and a range of shared scientific services, it’s the ideal place to support pioneering innovation. MSP’s unique partnership connections and support services can also open the doors to new regional and national networks and funding, providing opportunities that can transform businesses and help take them to the next level. The Park is home to national centres of excellence including the AMR Centre and Medicines Discovery Catapult, alongside a cluster of life science companies including Cancer Research UK, Concept Life Sciences and Evotec, to name a few.


Mrs Elaine Wilson
Business Development Manager 
Mr Keith Miller
Life Science Specialist 

Aptus Clinical Ltd

Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.

What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at 
a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.


Organisation type
Jonathan Lewis
Business Development Director 


Arcinova is a Contract Research and Development Organisation (CRDO), providing the pharmaceutical industry with a comprehensive range of services.

At Arcinova, we are focused on Process, Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covaering drug candidates in Development and launched to the Market.

Nathalie Huther
Business Development Manager Europe 

BioIndustry Association (BIA)

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

Michael McGivern
Membership and Business Development Manager 
Joanne Duffy

BioPartner UK

Exhibiting at Booth 38

BioPartner UK leads the UK Delegation to several partnering conferences
each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and
in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets. 

Organisation type
Lin Bateson
Chief Executive 


Biorelate, based at Manchester Science Park, combines natural language processing, AI and human expertise to mine and curate data from 50 million journals, patents and clinical trials.

Dr Daniel Jamieson
Mr Chris Hart
Lead Deployment Strategist 

Centre of Excellence in Infectious Diseases Research

CEIDR (Centre of Excellence in Infectious Diseases Research) is a partnership between the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool focused on translational partnering in infectious diseases. Liverpool has the largest concentration of translationally-focused public sector R&D expertise in infectious diseases in the UK, with a track record of working successfully with commercial partners to impact product development. Consequently, CEIDR is ideally positioned to develop partnerships between research and industry to address current and future health priorities.

CEIDR became fully operational in 2018 and will develop into the portal for external organisations to make connections, source expertise and resources in infectious diseases, building relationships with industry and academic organisations to advance drugs, vaccines and diagnostics towards market. The aim is for the CEIDR brand to become synonymous with excellence in infectious diseases R&D undertaken in LSTM, the University of Liverpool and our clinical partners in Liverpool and overseas.

Organisation type
Fiona Marston

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.

With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle. 


Organisation type
Paul Cronin
Russell Neal
Managing Director 

Crystec Ltd

CrystecPharma is a crystal and particle engineering company applying proprietary modified supercritical fluid (SCF) technologies to improve the performance of medicines. Our technology enables drug molecules to be crystallised in new forms and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Crystec has an enabling platform which can be applied to small and large molecules, to optimise a range of medicine dosage forms (e.g. oral, inhaled, intranasal, subcutaneous, sublingual).

Crystec works with the global pharmaceutical and health care industry to solve drug particle formation, formulation and process challenges. We are also developing our own innovative therapies in important areas of unmet clinical need, including women’s health, urology and treating respiratory disease. Crystec’s proprietary ‘mSAS’ (modified Supercritical Anti-Solvent) drug delivery technology is enabled by a highly efficient, stable and fully scalable manufacturing process and is approved by regulatory authorities. The mSAS platform creates unique opportunities to improve medicines in ways that can transform the quality of life for many patients.


Organisation type
Paul Thorning
Catherine Hunter
Business Development Director